ADAC issues restated financial numbers
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, this month issued restated financial results for the years 1996 through 1999 (see chart). At the same time, the company released financial results for the first quarter of 1999 (end-January) that
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, this month issued restated financial results for the years 1996 through 1999 (see chart). At the same time, the company released financial results for the first quarter of 1999 (end-January) that indicate that the restatement imbroglio has not slowed down the companys business prospects.
ADAC announced last year that it would restate its financial results for three years because of more stringent controls over how the company recognizes revenue. The company also adjusted some extraordinary charges taken during the three-year period. The restatements would not eliminate any sales, but rather would push them into later quarters, the company said. The announcement prompted a slide in ADACs stock and the filing of a half-dozen shareholder suits that the company is still defending (SCAN 1/13/99).
For the first quarter of fiscal 1999, ADAC posted sales of $94.3 million, an increase of 40% over the $64.7 million reported in the restated first quarter of 1998. The company recorded net income of $3.9 million, an amount that reflected the impact of $2.5 million in charges to restructure the companys international operations and $1.6 million in auditors and legal fees related to the restatement process. ADAC CEO Andrew Eckert said the company is optimistic about its prospects for 1999, and is booking orders in all its businesses at record rates.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
